Metabolic, inflammatory and haemostatic effects of a low-dose continuous combined HRT in women with type 2 diabetes: potentially safer with respect to vascular risk?
D001324:Autoantigens / Q000097:blood; D001786:Blood Glucose / Q000032:analysis; D002097:C-Reactive Protein / Q000032:analysis; D002318:Cardiovascular Diseases / Q000209:etiology; D008078:Cholesterol, LDL / Q000032:analysis; D003924:Diabetes Mellitus, Type 2 / Q000276:immunology / Q000378:metabolism*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004958:Estradiol / Q000008:administration & dosage*; D015914:Estrogen Replacement Therapy / Q000009:adverse effects; D005167:Factor VII / Q000032:analysis; D005260:Female; D006801:Humans; D015850:Interleukin-6 / Q000097:blood; D016014:Linear Models; D008593:Menopause; D008875:Middle Aged; D009640:Norethindrone / Q000008:administration & dosage*; D012307:Risk Factors; D010959:Tissue Plasminogen Activator / Q000276:immunology; D014280:Triglycerides / Q000097:blood
D001324:Autoantigens; D001786:Blood Glucose; D008078:Cholesterol, LDL; D015850:Interleukin-6; D014280:Triglycerides; D004958:Estradiol; D005167:Factor VII; D002097:C-Reactive Protein; D010959:Tissue Plasminogen Activator; D009640:Norethindrone